These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 12821831)

  • 1. Cost effective approaches to antimicrobial use in oncology patients.
    Goff DA
    Curr Opin Infect Dis; 2002 Dec; 15(6):565-8. PubMed ID: 12821831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monotherapy with piperacillin/tazobactam versus cefepime as empirical therapy for febrile neutropenia in pediatric cancer patients: a randomized comparison.
    Corapcioglu F; Sarper N; Zengin E
    Pediatr Hematol Oncol; 2006; 23(3):177-86. PubMed ID: 16517534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of the concepts of evidence-based medicine to the evidence on the treatment of febrile neutropenia].
    Jarque I; Sanz MA
    Enferm Infecc Microbiol Clin; 1999; 17 Suppl 2():95-102. PubMed ID: 10605194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
    Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
    Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time to clinical response: an outcome of antibiotic therapy of febrile neutropenia with implications for quality and cost of care.
    Elting LS; Rubenstein EB; Rolston K; Cantor SB; Martin CG; Kurtin D; Rodriguez S; Lam T; Kanesan K; Bodey G
    J Clin Oncol; 2000 Nov; 18(21):3699-706. PubMed ID: 11054443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic analysis of empirical therapy with ceftazidime alone or combination antibiotics for febrile neutropenia in cancer patients.
    Dranitsaris G; Tran TM; McGeer A; Narine L
    Pharmacoeconomics; 1995 Jan; 7(1):49-62. PubMed ID: 10155293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic treatment of febrile episodes in neutropenic cancer patients. Clinical and economic considerations.
    de Lalla F
    Drugs; 1997 May; 53(5):789-804. PubMed ID: 9129866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost.
    Corapçioglu F; Sarper N
    Pediatr Hematol Oncol; 2005; 22(1):59-70. PubMed ID: 15770833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer.
    Dranitsaris G
    Pharmacoeconomics; 1999 Oct; 16(4):343-53. PubMed ID: 10623363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empirical antibiotic therapy in the febrile neutropenic cancer patient: clinical efficacy and impact of monotherapy.
    Hathorn JW; Rubin M; Pizzo PA
    Antimicrob Agents Chemother; 1987 Jul; 31(7):971-7. PubMed ID: 3310871
    [No Abstract]   [Full Text] [Related]  

  • 12. Piperacillin/tazobactam: a pharmacoeconomic review of its use in moderate to severe bacterial infections.
    Young M; Plosker GL
    Pharmacoeconomics; 2001; 19(11):1135-75. PubMed ID: 11735679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fever and neutropenia in children with malignant disease.
    Roguin A; Kasis I; Ben-Arush MW; Sharon R; Berant M
    Pediatr Hematol Oncol; 1996; 13(6):503-10. PubMed ID: 8940733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cefpodoxime for antimicrobial prophylaxis in neutropenia: a retrospective case series.
    Wojenski DJ; Barreto JN; Wolf RC; Tosh PK
    Clin Ther; 2014 Jun; 36(6):976-81. PubMed ID: 24832560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Why empirical therapy?
    Klastersky J
    J Antimicrob Chemother; 2009 May; 63 Suppl 1():i14-5. PubMed ID: 19372173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of cost-effective antibiotic therapy in the management of infections in cancer patients.
    Cimino MA; Rotstein CM; Moser JE
    Ann Pharmacother; 1994 Jan; 28(1):105-11. PubMed ID: 8123946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antibiotic strategies in the febrile neutropenic patient].
    Marie JP
    Presse Med; 1998 Oct; 27(30):1554-6. PubMed ID: 9810315
    [No Abstract]   [Full Text] [Related]  

  • 18. Evolving concepts of management of febrile neutropenia in children with cancer.
    Orudjev E; Lange BJ
    Med Pediatr Oncol; 2002 Aug; 39(2):77-85. PubMed ID: 12116054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New strategies in the treatment of infectious complications in haematology and oncology: is there a role for out-patient antibiotic treatment of febrile neutropenia?
    Karthaus M; Carratalà J; Jürgens H; Ganser A
    Chemotherapy; 1998; 44(6):427-35. PubMed ID: 9755304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes and costs of febrile neutropenia: adventures in the science and art of treatment choices.
    Elting LS; Cantor SB
    Support Care Cancer; 2002 Apr; 10(3):189-96. PubMed ID: 11904783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.